RYDAPT
Total Payments
$5.9M
Transactions
7,047
Doctors
2,595
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $22,755 | 4 | 0 |
| 2023 | $9,095 | 8 | 0 |
| 2022 | $19,195 | 4 | 0 |
| 2021 | $299,781 | 37 | 26 |
| 2020 | $237,864 | 73 | 42 |
| 2019 | $782,593 | 318 | 121 |
| 2018 | $1.5M | 3,611 | 1,663 |
| 2017 | $3.0M | 2,992 | 1,687 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 277 | 77.1% |
| Consulting Fee | $552,949 | 140 | 9.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $500,248 | 162 | 8.5% |
| Travel and Lodging | $138,360 | 355 | 2.3% |
| Food and Beverage | $128,398 | 6,086 | 2.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $32,108 | 11 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $1,600 | 3 | 0.0% |
| Education | $9.49 | 13 | 0.0% |
Payments by Type
Research
$4.6M
277 transactions
General
$1.4M
6,770 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN LABEL MULTI CENTER EXPANDED TREATMENT PROTOCOL OF MIDOSTAURIN PKC412 IN PATIENTS 18 YEARS OF AGE OR OLDER WITH NEWLY DIAGNOSED FMS LIKE TYROSINE KINASE INDICATION ACUTE MYELOID LEUKEMIA AMLFLT3 MUTATED | Novartis Pharmaceuticals Corporation | $1.5M | 0 |
| PHASE II RANDOMIZED MULTI CENTER COMPARATIVE TRIAL OF MIDOSTAURIN MAINTENANCE TO PREVENT RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FLT3 ITD MUTATED AML | Novartis Pharmaceuticals Corporation | $1.2M | 0 |
| A PHASE III RANDOMIZED DOUBLE BLIND STUDY OF INDUCTION DAUNORUBICIN CYTARABINE AND CONSOLIDATION HIGH DOSE CYTARABINE CHEMOTHERAPY PLUS MIDOSTAURIN PKC412 OR PLACEBO IN NEWLY DIAGNOSED PATIENTS WITH FLT3 WILD TYPE FLT3 WT ACUTE MYELOID LEUKEMIA AML | Novartis Pharmaceuticals Corporation | $410,543 | 1 |
| A SINGLE ARM PHASE II OPEN LABEL STUDY TO DETERMINE THE EFFICACY OF 100MG TWICE DAILY ORAL DOSING OF MIDOSTAURIN ADMINISTERED TO PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS OR MAST CELL LEUKEMIA PLUS OR MINUS AN ASSOCIATED HEMATOLOGICAL CLONAL NON MAST CELL LINEAGE DISEASE | Novartis Pharmaceuticals Corporation | $406,181 | 0 |
| A RANDOMIZED PHASE II III TRIAL OF NOVEL THERAPEUTICS VERSUS AZACITIDINE IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA AGE 60 OR OLDER | Novartis Pharmaceuticals Corporation | $364,691 | 0 |
| AN OPEN LABEL MULTIPLE DOSE PARALLEL GROUP PHASE I STUDY TO ASSESS THE PHARMACOKINETICS AND SAFETY OF MIDOSTAURIN IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION AND SUBJECTS WITH NORMAL HEPATIC FUNCTION | Novartis Pharmaceuticals Corporation | $190,407 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $103,680 | 18 |
| A SINGLE ARM PHASE II OPEN LABEL STUDY TO DETERMINE THE EFFICACY OF 100MG TWICE DAILY ORAL DOSING OF MIDOSTAURIN ADMINISTERED TO PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS OR MAST CELL LEUKEMIA PLUS OR MINUS AN ASSOCIATED HEMATOLOGICAL CLONAL NON MAST | Novartis Pharmaceuticals Corporation | $66,167 | 0 |
| A SINGLE ARM PHASE II OPEN LABEL STUDY TO DETERMINE THE EFFICACY OF TWICE DAILY ORAL DOSING OF PKC412 ADMINISTERED TO PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS ASM AND MAST CELL LEUKEMIA PLUS OR MINUS HEMATOLOGICAL CLONAL NON MAST CELL LINEAGE DISEASE | Novartis Pharmaceuticals Corporation | $62,101 | 0 |
| COMBINATION OF MIDOSTAURIN AND DECITABINE AS A FRONT LINE THERAPY FOR ELDERLY PATIENTS WITH AML NOT FIT FOR INTENSIVE CHEMOTHERAPY | Novartis Pharmaceuticals Corporation | $56,750 | 0 |
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $36,650 | 0 |
| A PHASE II, OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF TWICE DAILY MIDOSTAURIN (PKC412) COMBINED WITH STANDARD CHEMOTHERAPY AND AS A SINGLE AGENT POST-CONSOLIDATION THERAPY IN CHILDREN WITH UNTREATED FLT3-MUTATE | Novartis Pharmaceuticals Corporation | $34,192 | 0 |
| A PHASE I STUDY OF CHEMORADIATION WITH MIDOSTAURIN PKC412 FOR LOCALLY ADVANCED RECTAL CANCER | Novartis Pharmaceuticals Corporation | $27,277 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $22,824 | 11 |
| A phase III randomized double blind study of induction daunorubicin cytarabine and consolidation high dose cytarabine chemotherapy plus midostaurin PKC412 or placebo in newly diagnosed patients with FLT3 wild type FLT3 wt acute myeloid leukemia AML | Novartis Pharmaceuticals Corporation | $22,062 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $20,905 | 14 |
| A PHASE I AND OR II STUDY OF MIDOSTAURIN PKC412 AND 5 AZACITIDINE FOR ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA | Novartis Pharmaceuticals Corporation | $10,400 | 0 |
| A phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AML | Novartis Pharmaceuticals Corporation | $9,788 | 0 |
| DECITABINE IN COMBINATION WITH MIDOSTAURIN FOR ELDERLY PATIENTS WITH FLT3 ITD AND OR TKD POSITIVE AML | Novartis Pharmaceuticals Corporation | $8,090 | 0 |
| A PHASE III RANDOMIZED DOUBLE BLIND STUDY OF INDUCTION DAUNORUBICIN AND OR CYTARABINE AND CONSOLIDATION HIGH DOSE CYTARABINE CHEMOTHERAPY PLUS MIDOSTAURIN PKC412IND NUMBER 101261 OR PLACEBO IN NEWLY DIAGNOSED PATIENTS LESS THAN 60 YEARS OF AGE WITH FLT3 M | Novartis Pharmaceuticals Corporation | $4,256 | 0 |
Top Doctors Receiving Payments for RYDAPT — Page 104
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology | Lady Lake, FL | $5.98 | 1 |
| , MD | Pediatrics | Rexburg, ID | $5.59 | 2 |
| , M.D | Hematology & Oncology | Moline, IL | $5.58 | 1 |
| , M.D | Hematology & Oncology | Salt Lake City, UT | $5.22 | 1 |
| , MD | Medical Oncology | East Stroudsburg, PA | $4.84 | 1 |
| , MD | Hematology & Oncology | Tallahassee, FL | $4.32 | 1 |
| , M.D | Internal Medicine | Tallahassee, FL | $4.32 | 1 |
| , MD | Internal Medicine | Tallahassee, FL | $4.32 | 1 |
| , M.D | Internal Medicine | Tallahassee, FL | $4.32 | 1 |
| , MD | Internal Medicine | Las Vegas, NV | $4.02 | 1 |
| , M.D | Medical Oncology | Dallas, TX | $4.00 | 1 |
| , M.D | Medical Oncology | Columbus, OH | $3.63 | 1 |
| , MD | Internal Medicine | Visalia, CA | $2.67 | 1 |
| , MD | Medical Oncology | Santa Fe, NM | $2.48 | 1 |
| , M.D | Hematology & Oncology | Scottsbluff, NE | $0.73 | 1 |
| , M.D | Hematology & Oncology | Rancho Cucamonga, CA | $0.73 | 1 |
| , MD | Hematology & Oncology | Denver, CO | $0.73 | 1 |
| , M.D | Internal Medicine | Casper, WY | $0.73 | 1 |
| , M.D | Hematology | Golden, CO | $0.73 | 1 |
| , M.D | Hematology & Oncology | Scottsbluff, NE | $0.73 | 1 |
| , D.O | Medical Oncology | Klamath Falls, OR | $0.38 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.9M
- Total Doctors 2,595
- Transactions 7,047
About RYDAPT
RYDAPT is a drug associated with $5.9M in payments to 2,595 healthcare providers, recorded across 7,047 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2024. In 2024, $22,755 was paid across 4 transactions to 0 doctors.
The most common payment nature for RYDAPT is "Unspecified" ($4.6M, 77.1% of total).
RYDAPT is associated with 20 research studies, including "AN OPEN LABEL MULTI CENTER EXPANDED TREATMENT PROTOCOL OF MIDOSTAURIN PKC412 IN PATIENTS 18 YEARS OF AGE OR OLDER WITH NEWLY DIAGNOSED FMS LIKE TYROSINE KINASE INDICATION ACUTE MYELOID LEUKEMIA AMLFLT3 MUTATED" ($1.5M).